They had so much confidence about the safety of the drug that they put a statement saying that the drug did not cause the deaths of the patients in p2 because they saw none in the other trials. The stellar p2 data, the p-values assigned to it, and the identical design for the p3 is what bolstered my confidence that the p3 data would meet the endpoints and more. The drug is firing on all cylinders. Any miscue now will be on the part of the management but this management seems to be more level headed than the others I’ve seen. But I was a little worried about what CoolG said on the race makeup knowing that the data on the p2 trial about that race group was not encouraging but then again I held on to my conviction that they know what they’re doing. One upgrade from a big brokerage firm will expedite our trek to the north. The research you provided about the drug was the one that kept us motivated to repeat the positive narrative again and again especially the p- values.
News 
Market Data 
Discover 
AI
